Pramlintide Acetate Patent Expiration
Pramlintide Acetate is Used for managing diabetes by regulating blood sugar levels and reducing post-prandial hyperglycemia. It was first introduced by Astrazeneca Ab
Pramlintide Acetate Patents
Given below is the list of patents protecting Pramlintide Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Symlin | US5686411 | Amylin agonist peptides and uses therefor |
Mar 16, 2019
(Expired) | Astrazeneca Ab |
| Symlin | US6114304 | Methods for regulating gastrointestinal motility |
Sep 05, 2017
(Expired) | Astrazeneca Ab |
| Symlin | US5814600 | Method and composition for treatment of insulin requiring mammals |
Sep 29, 2015
(Expired) | Astrazeneca Ab |
| Symlin | US6608029 | Methods for regulating gastrointestinal motility |
Sep 07, 2013
(Expired) | Astrazeneca Ab |
Pramlintide Acetate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List